81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results

Abstract

Previously, the interim analysis of the multicenter, single-arm, phase 2 NEOS study (ChiCTR1800016948) demonstrated the promising efficacy and tolerable safety profile of neoadjuvant osimertinib in patients with resectable EGFR mutated NSCLC. Here we present the final efficacy and safety results of neoadjuvant osimertinib.